Univest
Univest
  • Markets

3 Oncology Medicines Firm, Fluorochemicals Producer and Hospital Software Provider Stocks With a Strong Future Roadmap: Natco Pharma, Navin Fluorine International and Inventurus Knowledge Solutions

  • November 19, 2026
  • Posted by: Kunal Singla
  • Category: Best Stocks
No Comments
3 Oncology Medicines Firm, Fluorochemicals Producer and Hospital Software Provider Stocks With a Strong Future Roadmap: Natco Pharma, Navin Fluorine International and Inventurus Knowledge Solutions

Natco Pharma, Navin Fluorine International and Inventurus Knowledge Solutions: ROE of 15.4% to 25.8% and FY22 to FY26 revenue CAGR of 21.0% to 42.2%. Prices as of 18 Nov 2026.

Quick Answer

The three cancer drug, fluorine and health IT stocks to watch are Natco Pharma, Navin Fluorine International and Inventurus Knowledge Solutions. Their return on equity ranges from 15.4% to 25.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 21.0% to 42.2%. Inventurus Knowledge Solutions leads on both return on equity at 25.8% and revenue growth at 42.2% a year. Prices are based on the 18 November 2026 close, and this article is educational, not investment advice.

Cancer drug, fluorine and health IT stocks let investors follow companies that serve a growing part of the Indian economy. Natco Pharma, Navin Fluorine International and Inventurus Knowledge Solutions cover a specialty drugs maker, a fluorine chemicals maker and a healthcare IT services company.

This list covers three cancer drug, fluorine and health IT stocks with complete current figures: Natco Pharma, Navin Fluorine International and Inventurus Knowledge Solutions. Every figure comes from the latest reported financials and the 18 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • What Are Cancer Drug, Fluorine and Health IT Stocks?
  • Cancer Drug, Fluorine and Health IT Stocks at a Glance
  • Why Do Cancer Drug, Fluorine and Health IT Stocks Have a Strong Roadmap in India?
  • Why Natco Pharma Features Among These Cancer Drug, Fluorine and Health IT Stocks
  • Why Navin Fluorine International Features Among These Cancer Drug, Fluorine and Health IT Stocks
  • Why Inventurus Knowledge Solutions Features Among These Cancer Drug, Fluorine and Health IT Stocks
  • Natco Pharma vs Navin Fluorine International vs Inventurus Knowledge Solutions on Key Financials
  • Key Risks to Check Before Investing in Cancer Drug, Fluorine and Health IT Stocks
  • Final Thoughts on Cancer Drug, Fluorine and Health IT Stocks
    • What are cancer drug, fluorine and health IT stocks?
    • Which cancer drug, fluorine and health IT stocks are covered in this list?
    • Why do cancer drug, fluorine and health IT stocks have a strong future roadmap in India?
    • How has Natco Pharma performed financially?
    • How has Navin Fluorine International performed financially?
    • How has Inventurus Knowledge Solutions performed financially?
    • What risks should investors check before buying cancer drug, fluorine and health IT stocks?
    • Is this list of cancer drug, fluorine and health IT stocks investment advice?

What Are Cancer Drug, Fluorine and Health IT Stocks?

Cancer drug, fluorine and health IT stocks are listed companies that make specialty medicines for cancer and other serious conditions, make fluorine based chemicals for cooling, batteries and drugs, and provide technology and data services to healthcare providers. Their earnings depend on medicine demand, specialty chemical orders and healthcare technology budgets.

Cancer Drug, Fluorine and Health IT Stocks at a Glance

Company CMP (Rs) Market Cap (Rs Cr) P/E Industry P/E ROE (%) D/E
Natco Pharma 820.6 15,708 13.7 36.0 15.4 0.08
Navin Fluorine International 10,278 41,847 53.0 35.1 16.7 0.32
Inventurus Knowledge Solutions 1,610.1 29,242 38.3 17.6 25.8 0.27

On valuation, Natco Pharma trades at a P/E below the industry P/E, while Navin Fluorine International and Inventurus Knowledge Solutions trade above it, which reflects the growth the market already expects. Readers comparing cancer drug, fluorine and health IT stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in cancer drug, fluorine and health IT stocks can use the coming numbers to test whether growth is holding.

Why Do Cancer Drug, Fluorine and Health IT Stocks Have a Strong Roadmap in India?

Cancer drug, fluorine and health IT stocks have a strong roadmap in India because rising demand for advanced medicines, rising demand for fluorine chemicals and wider healthcare digitisation keep widening the market for these companies.

  • Specialty drugs. Patients need advanced treatments.
  • Fluorine chemicals. Cooling and battery makers need fluorine inputs.
  • Healthcare IT. Providers digitise their operations.

Why Natco Pharma Features Among These Cancer Drug, Fluorine and Health IT Stocks

Among the cancer drug, fluorine and health IT stocks on this list, Natco Pharma is a Hyderabad-based pharmaceutical company focused on complex generics, oncology, and active ingredients, with a significant presence in the United States and other regulated markets.

Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%.

The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P/E of 13.7, below the industry P/E of 36.0.

Roadmap: The company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.

What to watch: Check the timing of key product launches in the US and the contribution from new drug approvals.

Why Navin Fluorine International Features Among These Cancer Drug, Fluorine and Health IT Stocks

Among the oncology generics, refrigerant inputs and hospital software shares on this list, Navin Fluorine International is a specialty fluorine chemicals company that makes refrigerant gases, specialty fluorochemicals, and custom research and manufacturing services for pharma and agrochemical clients.

In the June 2026 quarter, revenue grew 46.1% year on year to Rs 1,080 crore, while net profit rose 107.7% to Rs 243 crore. Revenue rose from Rs 1,493 crore in FY22 to Rs 3,379 crore in FY26, a compound annual growth rate of 22.7%.

Net profit grew from Rs 263 crore in FY22 to Rs 664 crore in FY26, which works out to a compound annual growth rate of 26.0%. The company has a return on equity of 16.7%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 41,847 crore. The stock trades at a P/E of 53.0, above the industry P/E of 35.1.

Roadmap: Growth is driven by specialty chemicals, contract manufacturing for global partners and new fluorination capacity. The company has also added capacity for products linked to battery and clean energy applications.

What to watch: Check the ramp-up of new capacity and the share of the contract manufacturing business in revenue.

Why Inventurus Knowledge Solutions Features Among These Cancer Drug, Fluorine and Health IT Stocks

Among the three companies on this list, Inventurus Knowledge Solutions, known as IKS, is a Mumbai-based healthcare technology and services company that supports healthcare providers and payors in the United States with analytics, clinical coding and technology platforms.

The company has a return on equity of 25.8%, a debt to equity ratio of 0.27 and a market capitalisation of Rs 29,242 crore. The stock trades at a P/E of 38.3, above the industry P/E of 17.6.

Revenue rose from Rs 784 crore in FY22 to Rs 3,211 crore in FY26, a compound annual growth rate of 42.2%. Net profit grew from Rs 233 crore in FY22 to Rs 722 crore in FY26, which works out to a compound annual growth rate of 32.7%. In the June 2026 quarter, revenue grew 21.0% year on year to Rs 899 crore, while net profit rose 27.8% to Rs 194 crore.

Roadmap: The company is widening its technology-led services for risk adjustment, care coordination and revenue cycle work. Long-term relationships with large healthcare organisations give it recurring demand.

What to watch: Follow client additions, platform adoption and healthcare policy changes in the United States.

Natco Pharma vs Navin Fluorine International vs Inventurus Knowledge Solutions on Key Financials

The table below sets the three cancer drug, fluorine and health IT stocks side by side on revenue, profit and margin, using reported figures.

Company FY22 Revenue (Rs Cr) FY26 Revenue (Rs Cr) Revenue CAGR (FY22-FY26) FY26 Net Profit (Rs Cr) FY26 Net Margin
Natco Pharma 2,044 4,376 21.0% 1,372 31.4%
Navin Fluorine International 1,493 3,379 22.7% 664 19.6%
Inventurus Knowledge Solutions 784 3,211 42.2% 722 22.5%

Inventurus Knowledge Solutions posts the highest return on equity in this group at 25.8%. Natco Pharma has the largest FY26 revenue at Rs 4,376 crore, and Inventurus Knowledge Solutions shows the fastest revenue growth with a 42.2% compound annual rate. A useful habit with cancer drug, fluorine and health IT stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Cancer Drug, Fluorine and Health IT Stocks

Every theme carries risks that deserve a check before any decision. For these cancer drug, fluorine and health IT stocks, the main points are: Long-term oncology generics, refrigerant inputs and hospital software shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

  • Regulatory approvals. Plant inspections and approvals can affect supplies.
  • Raw material and energy costs. Input prices can move margins in chemicals.
  • Client spending. Technology budgets can vary with global conditions.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter cancer drug, fluorine and health IT stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Cancer Drug, Fluorine and Health IT Stocks

Cancer drug, fluorine and health IT stocks reward investors who follow demand trends, order books and margins together. Natco Pharma, Navin Fluorine International and Inventurus Knowledge Solutions each have a clear plan to grow. Based on the 18 November 2026 close, Natco Pharma trades at Rs 820.6, Navin Fluorine International at Rs 10,278 and Inventurus Knowledge Solutions at Rs 1,610.1. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these cancer drug, fluorine and health IT stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track cancer drug, fluorine and health IT stocks, set price alerts and get research-backed stock ideas.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

What are cancer drug, fluorine and health IT stocks?

Ans. Cancer drug, fluorine and health IT stocks are listed companies that make specialty medicines for cancer and other serious conditions, make fluorine based chemicals for cooling, batteries and drugs, and provide technology and data services to healthcare providers. Their earnings depend on medicine demand, specialty chemical orders and healthcare technology budgets. This list looks at three of them, Natco Pharma, Navin Fluorine International and Inventurus Knowledge Solutions, using reported FY22 to FY26 financials and the 18 November 2026 closing prices.

Which cancer drug, fluorine and health IT stocks are covered in this list?

Ans. This list covers Natco Pharma, Navin Fluorine International and Inventurus Knowledge Solutions. Based on the 18 November 2026 close, Natco Pharma traded at Rs 820.6, Navin Fluorine International at Rs 10,278 and Inventurus Knowledge Solutions at Rs 1,610.1. Their return on equity ranges from 15.4% to 25.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 21.0% to 42.2%.

Why do cancer drug, fluorine and health IT stocks have a strong future roadmap in India?

Ans. Cancer drug, fluorine and health IT stocks have a strong roadmap in India because rising demand for advanced medicines, rising demand for fluorine chemicals and wider healthcare digitisation keep widening the market for these companies. The main drivers are as follows. Specialty drugs. Patients need advanced treatments. Fluorine chemicals. Cooling and battery makers need fluorine inputs. Healthcare IT. Providers digitise their operations. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Natco Pharma performed financially?

Ans. Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%. The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P/E of 13.7, below the industry P/E of 36.0. Looking ahead, the company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.

How has Navin Fluorine International performed financially?

Ans. Revenue rose from Rs 1,493 crore in FY22 to Rs 3,379 crore in FY26, a compound annual growth rate of 22.7%. Net profit grew from Rs 263 crore in FY22 to Rs 664 crore in FY26, which works out to a compound annual growth rate of 26.0%. In the June 2026 quarter, revenue grew 46.1% year on year to Rs 1,080 crore, while net profit rose 107.7% to Rs 243 crore. The company has a return on equity of 16.7%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 41,847 crore. The stock trades at a P/E of 53.0, above the industry P/E of 35.1. Looking ahead, growth is driven by specialty chemicals, contract manufacturing for global partners and new fluorination capacity. The company has also added capacity for products linked to battery and clean energy applications.

How has Inventurus Knowledge Solutions performed financially?

Ans. Revenue rose from Rs 784 crore in FY22 to Rs 3,211 crore in FY26, a compound annual growth rate of 42.2%. Net profit grew from Rs 233 crore in FY22 to Rs 722 crore in FY26, which works out to a compound annual growth rate of 32.7%. In the June 2026 quarter, revenue grew 21.0% year on year to Rs 899 crore, while net profit rose 27.8% to Rs 194 crore. The company has a return on equity of 25.8%, a debt to equity ratio of 0.27 and a market capitalisation of Rs 29,242 crore. The stock trades at a P/E of 38.3, above the industry P/E of 17.6. Looking ahead, the company is widening its technology-led services for risk adjustment, care coordination and revenue cycle work. Long-term relationships with large healthcare organisations give it recurring demand.

What risks should investors check before buying cancer drug, fluorine and health IT stocks?

Ans. Investors should check a few risks before buying cancer drug, fluorine and health IT stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Raw material and energy costs. Input prices can move margins in chemicals. Client spending. Technology budgets can vary with global conditions. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of cancer drug, fluorine and health IT stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 18 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.



Best Stocks cancer drug fluorine and health IT stocks fluorine chemistry and healthcare IT services stocks Inventurus Knowledge Solutions Natco Pharma Navin Fluorine International oncology generics refrigerant inputs and hospital software shares specialty drugs
Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply